imupret n 1 ml/ml krople doustne
bionorica se - extractum compositum (1:38) ex: equiseti herba, millefolii herba, altheae radice, juglandis folio, taraxaci herba, matricariae flore, quercus cortice - krople doustne - 1 ml/ml
influvac tetra - zawiesina do wstrzykiwań w ampułko-strzykawce
viatris healthcare limited - vaccinum influenzae inactivatum ex corticis antigeniis praeparatum - zawiesina do wstrzykiwań w ampułko-strzykawce - -
bortezomib medac 3,5 mg proszek do sporządzania roztworu do wstrzykiwań
medac gmbh - bortezomibum - proszek do sporządzania roztworu do wstrzykiwań - 3,5 mg
bortezomib medac 1 mg proszek do sporządzania roztworu do wstrzykiwań
medac gmbh - bortezomibum - proszek do sporządzania roztworu do wstrzykiwań - 1 mg
bortezomib msn 3,5 mg proszek do sporządzania roztworu do wstrzykiwań
vivanta generics s.r.o. - bortezomibum - proszek do sporządzania roztworu do wstrzykiwań - 3,5 mg
kymriah
novartis europharm limited - tisagenlecleucel - precursor b-cell lymphoblastic leukemia-lymphoma; lymphoma, large b-cell, diffuse - inne środki przeciwnowotworowe - kymriah is indicated for the treatment of:• paediatric and young adult patients up to and including 25 years of age with b cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post transplant or in second or later relapse. • adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl) after two or more lines of systemic therapy. • adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.
yescarta
kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - Środki przeciwnowotworowe - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.
breyanzi
bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - Środki przeciwnowotworowe - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.
bortezomib mylan 1 mg proszek do sporządzania roztworu do wstrzykiwań
mylan s.a.s. - bortezomibum - proszek do sporządzania roztworu do wstrzykiwań - 1 mg
bortezomib mylan 3,5 mg proszek do sporządzania roztworu do wstrzykiwań
mylan s.a.s. - bortezomibum - proszek do sporządzania roztworu do wstrzykiwań - 3,5 mg